159 related articles for article (PubMed ID: 27422136)
21. Haemoglobin A1c: comparing performance of two point of care devices with laboratory analyser.
Wan Mohd Zin RM; Ahmad Kamil ZI; Tuan Soh TR; Embong M; Wan Mohamud WN
BMC Res Notes; 2013 Dec; 6():540. PubMed ID: 24344903
[TBL] [Abstract][Full Text] [Related]
22. Validation of a point of care lipid analyser using a hospital based reference laboratory.
Carey M; Markham C; Gaffney P; Boran C; Maher V
Ir J Med Sci; 2006; 175(4):30-5. PubMed ID: 17312826
[TBL] [Abstract][Full Text] [Related]
23. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
[TBL] [Abstract][Full Text] [Related]
24. Performance of Afinion HbA1c measurements in general practice as judged by external quality assurance data.
Stavelin A; Flesche K; Tollaanes M; Christensen NG; Sandberg S
Clin Chem Lab Med; 2020 Mar; 58(4):588-596. PubMed ID: 31821164
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of point-of-care HbA1c testing in pregnant women.
Culliney K; McCowan LME; Okesene-Gafa K; Murphy R; Rowan J; Taylor RS; Mckinlay CJD;
Aust N Z J Obstet Gynaecol; 2018 Dec; 58(6):643-647. PubMed ID: 29468638
[TBL] [Abstract][Full Text] [Related]
26. Status of non-HDL-cholesterol and LDL-cholesterol among subjects with and without metabolic syndrome.
Khan SH; Asif N; Ijaz A; Manzoor SM; Niazi NK; Fazal N
J Pak Med Assoc; 2018 Apr; 68(4):554-558. PubMed ID: 29808044
[TBL] [Abstract][Full Text] [Related]
27. Development of a target product profile for a point-of-care cardiometabolic device.
Vetter B; Beran D; Boulle P; Chua A; de la Tour R; Hattingh L; Perel P; Roglic G; Sampath R; Woodman M; Perone SA
BMC Cardiovasc Disord; 2021 Oct; 21(1):486. PubMed ID: 34627153
[TBL] [Abstract][Full Text] [Related]
28. Clinical correlation between a point-of-care testing system and laboratory automation for lipid profile.
Ferreira CE; França CN; Correr CJ; Zucker ML; Andriolo A; Scartezini M
Clin Chim Acta; 2015 Jun; 446():263-6. PubMed ID: 25952166
[TBL] [Abstract][Full Text] [Related]
29. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
30. Low density lipoprotein particle size is associated with glycosylated hemoglobin levels regardless of plasma lipid levels.
Okumura K; Matsui H; Kawakami K; Numaguchi Y; Hayakawa M; Morishima I; Toki Y; Ito T
Intern Med; 1998 Mar; 37(3):273-9. PubMed ID: 9617862
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein abnormalities in well-treated type II diabetic patients.
Manzato E; Zambon A; Lapolla A; Zambon S; Braghetto L; Crepaldi G; Fedele D
Diabetes Care; 1993 Feb; 16(2):469-75. PubMed ID: 8432219
[TBL] [Abstract][Full Text] [Related]
32. Geographic variation in cardiometabolic risk distribution: A cross-sectional study of 256,525 adult residents in the Illawarra-Shoalhaven region of the NSW, Australia.
Toms R; Mayne DJ; Feng X; Bonney A
PLoS One; 2019; 14(10):e0223179. PubMed ID: 31574124
[TBL] [Abstract][Full Text] [Related]
33. Comparing the Accuracy of 2 Point-of-Care Lipid Testing Devices.
Bastianelli K; Ledin S; Chen J
J Pharm Pract; 2017 Oct; 30(5):490-497. PubMed ID: 27313238
[TBL] [Abstract][Full Text] [Related]
34. Fingerstick Precision and Total Error of a Point-of-Care HbA1c Test.
Arnold WD; Kupfer K; Hvidsten Swensen M; Fortner KS; Bays HE; Davis M; Klaff LJ; San George RC
J Diabetes Sci Technol; 2020 Sep; 14(5):890-895. PubMed ID: 30841743
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.
Soran H; Liu Y; Adam S; Siahmansur T; Ho JH; Schofield JD; Kwok S; Gittins M; France M; Younis N; Gibson JM; Durrington PN; Rutter MK
J Clin Lipidol; 2018; 12(1):44-55. PubMed ID: 29246729
[TBL] [Abstract][Full Text] [Related]
36. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
Florakis D; Hung V; Kaltsas G; Coyte D; Jenkins PJ; Chew SL; Grossman AB; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2000 Oct; 53(4):453-9. PubMed ID: 11012570
[TBL] [Abstract][Full Text] [Related]
37. A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus.
Winocour PH; Durrington PN; Bhatnagar D; Mbewu AD; Ishola M; Mackness M; Arrol S
Diabetes Res Clin Pract; 1992 Dec; 18(3):173-84. PubMed ID: 1289018
[TBL] [Abstract][Full Text] [Related]
38. Multicenter assessment of a hemoglobin A1c point-of-care device for diagnosis of diabetes mellitus.
Sobolesky PM; Smith BE; Saenger AK; Schulz K; Apple FS; Scott MG; Wu AHB; Little RR; Fitzgerald RL
Clin Biochem; 2018 Nov; 61():18-22. PubMed ID: 30236830
[TBL] [Abstract][Full Text] [Related]
39. Sex differences in the effect of HbA1c-defined diabetes on a wide range of cardiovascular disease risk factors.
Du T; Yuan G; Zhou X; Sun X
Ann Med; 2016; 48(1-2):34-41. PubMed ID: 26758477
[TBL] [Abstract][Full Text] [Related]
40. Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes.
O'Brien SF; Watts GF; Powrie JK; Shaw KM; Miller NJ
Diabetes Res Clin Pract; 1996 Apr; 32(1-2):81-90. PubMed ID: 8803485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
